KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Esperion Therapeutics (ESPR) EBIT (2018 - 2025)

Esperion Therapeutics (ESPR) has disclosed EBIT for 8 consecutive years, with $85.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBIT rose 2028.35% year-over-year to $85.2 million, compared with a TTM value of $60.3 million through Dec 2025, up 10.79%, and an annual FY2025 reading of $60.3 million, up 10.79% over the prior year.
  • EBIT was $85.2 million for Q4 2025 at Esperion Therapeutics, up from -$10.0 million in the prior quarter.
  • Across five years, EBIT topped out at $85.2 million in Q4 2025 and bottomed at -$82.8 million in Q1 2021.
  • Average EBIT over 5 years is -$22.4 million, with a median of -$34.8 million recorded in 2021.
  • Peak annual rise in EBIT hit 2028.35% in 2025, while the deepest fall reached 130.57% in 2025.
  • Year by year, EBIT stood at -$55.6 million in 2021, then increased by 23.58% to -$42.5 million in 2022, then increased by 0.34% to -$42.4 million in 2023, then soared by 89.57% to -$4.4 million in 2024, then surged by 2028.35% to $85.2 million in 2025.
  • Business Quant data shows EBIT for ESPR at $85.2 million in Q4 2025, -$10.0 million in Q3 2025, and $7.1 million in Q2 2025.